Dr. Reddy's Laboratories
DRREDDY · NSE · Pharma · India
Revenue (FY2026)
₹33,593 Cr
Net margin
12.8%
New to these? P/E, ROE, ROCE and more in Learn.
Ask MarketChacha about DRREDDY
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 9, 2026
Dr Reddy's shares fell ~6% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingredient (API) in certain batches.
source 1 ↗· confidence: high
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Revenue trend
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹33,593 Cr | ₹4,285 Cr | 12.8% |
| FY2025 | ₹32,554 Cr | ₹5,654 Cr | 17.4% |
| FY2024 | ₹27,916 Cr | ₹5,578 Cr | 20.0% |
| FY2023 | ₹24,670 Cr | ₹4,507 Cr | 18.3% |
Quarterly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| 2026Q1 | ₹7,516 Cr | ₹220 Cr | 2.9% |
| 2025Q4 | ₹8,727 Cr | ₹1,210 Cr | 13.9% |
| 2025Q3 | ₹8,805 Cr | ₹1,437 Cr | 16.3% |
| 2025Q2 | ₹8,545 Cr | ₹1,418 Cr | 16.6% |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/9/2026Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-26
BSE6/30/2026Dr Reddys Laboratories Ltd - 500124 - Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed Business Responsibility and Sustainability Report FY 2026
BSE6/30/2026Please find enclosed Notice of the 42nd Annual General Meeting of the Company.
BSE6/30/2026materialDr Reddys Laboratories Ltd - 500124 - Reg. 34 (1) Annual Report.
Please find enclosed Integrated Annual Report FY 2025-26
BSE6/30/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE6/25/2026Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
BSE6/22/2026material
In the news
- Hsbc Holdings PLC Sells 111,151 Shares of Dr. Reddy's Laboratories Ltd $RDYMarketBeat · 7/14/2026
- Dr Reddy's shares: Semaglutide woes to trigger EPS cuts; Should you buy, sell or hold?Business Today · 7/13/2026
- Dr Reddy's faces semaglutide setback, but Nomura keeps 'Buy'; here's why it sees Rs 1,740 targetMoneycontrol.com · 7/13/2026
- Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption.The Economic Times · 7/10/2026
- Dr. Reddy's Shares Extend Fall For Second Day As Semaglutide Quality Concerns PrevailNDTV Profit · 7/10/2026
- Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key clientCNBC TV18 · 7/10/2026
- Dr Reddy's stock extends slide as brokerages trim estimates amid semaglutide setbackMoneycontrol.com · 7/10/2026
- Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?Business Standard · 7/10/2026
Education and discussion only — not investment advice. Data from official filings (SEC/BSE), reported company financials, and news — not live exchange quotes. Verify with the linked sources before acting.